Arancibia Y

ORCID: 0000-0001-7453-7300 · 1 paper in corpus

2026

More than alternative estrogen receptors: the emerging role of GPER-1 and ERα36 in breast cancer.

Exploration of targeted anti-tumor therapy ·doi:10.37349/etat.2026.1002377

Breast cancer classification and therapeutic decision-making have traditionally relied on the evaluation of estrogen receptor alpha (ERα), PR, and HER2, yet this framework does not fully explain tumor heterogeneity, endocrine resistance, or…